Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is presently working on the advancement of its Sol-gel drug delivery research program. An article discussing the company reads: “Currently, the company’s research is focused on testing various cannabis strains for the purpose of formulating potent and effective Sol-gels. PreveCeutical Chief Research Officer Dr. Harendra Parekh is leading the program. … In addition, various spray devices have already been tested. According to PreveCeutical CEO and President Stephen Van Deventer, a focus on safety regulations and a tamper-proof delivery system will be of paramount importance. While the Sol-gel program is still in its early phases, the evaluation of delivery systems alongside the cannabis strain testing demonstrates a strong commitment to having a working innovative treatment product on the market.”
To view the full article, visit http://cnw.fm/G68qn
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com
More from CannabisNewsBreaks
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Golden Triangle Ventures (OTC: GTVH) (“GTV”) has completed a major restructuring of its capital structure and…
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with…
CannabisNewsWire (CNW), a trusted communications platform within the cannabis sector and a part of InvestorBrandNetwork…
Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…
WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…
Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…